Company intelligence / Profile preview

Otovia Therapeutics

Suzhou, Jiangsu Sheng, Chinaorpha.net ↗

Ownership: Private
Development stage: Phase 1

Overview

OTOV-101, designed for DFNB9 deafness, began IIT clinical trial in June 2023 with exceptional clinical efficacy. Patients with congenital deafness experienced hearing restoration post-treatment. Clinical data published in Advanced Science in January 2024, marking the world's first formal report on clinical application of gene therapy for deafness. Over 10 patients have been successfully treated, with the longest follow-up exceeding 1.5 years.

Therapeutic areas: Neurology
Modalities: AAV-based gene therapyGene editingGene therapy
Industry: Biotech

Drug pipeline

3 assets

OTOV101

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Fosun PharmaSoutheast UniversityLeading hospitals in China

Beyond the preview

Go deeper on Otovia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otovia Therapeutics.

Explore the full profile